We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




HIV Test Recommended When Specific Indicator Diseases Present

By LabMedica International staff writers
Posted on 21 Mar 2012
Heterosexuals are at particular risk of carrying the Human immunodeficiency virus (HIV) for so long that they remain undiagnosed until their immune system starts to fail and they become ill. More...


It has recently been revealed that a number of diseases, including herpes zoster and certain forms of cancer, should be on the list of indicators for having HIV, and thus serve to prompt health care professionals to suggest an HIV-test to their patients.

An international study under the leadership of the HIV in Europe initiative (Copenhagen, Denmark) and under the auspices of the University of Copenhagen (Denmark) will debate how to disseminate knowledge of the new HIV indicator diseases to non-HIV doctors and health care professionals across Europe. The HIV in Europe initiative took up this challenge in 2009 and started the study HIV Indicator Diseases Across Europe (HIDES), which investigated eight new diseases and how often they proved to be signs of an undiagnosed HIV infection among the 3,588 patients in the study.

The sooner HIV-infected individuals receive a diagnosis and start therapy, the greater are their chances of survival and their quality of life. Investigators have shown that therapy lowers the risk of passing the infection on to someone else. Half of all people living with HIV are diagnosed very late in the course of their chronic HIV infection. People infected through heterosexual transmission now comprise 42 % of these late presenters, as a study of 90,000 Europeans tested HIV positive since 2000 shows. The Joint United Nations Program on HIV and AIDS, known as UNAIDS, has estimated that 2.5 million Europeans carry an HIV infection, and as many as 900,000 of these, are still unaware of this. Inside the European Union, the numbers are 800,000 infected with 250,000 undiagnosed.

Jens Lundgren, MD, the chief physician and director of the Copenhagen HIV Program, said " We could see that if an adult had a sexually transmitted infection, malignant lymphoma, cervical or anal cancer/dysplasia, herpes zoster, hepatitis B or C, ongoing mononucleosis-like illness, inexplicable, persistent decline in the number of circulating white blood cells, or seborrheic dermatitis/exanthema, the risk of HIV infection was so high that it would be cost-effectiveness for society to routinely offer them a test". He added, "The incidence of HIV is greater for these eight indicator diseases and they should encourage health care professionals to offer the patient an HIV test. Draft guidelines on how to ensure this throughout Europe are one of the topics we need to debate and decide on, before they can be implemented." The new results and guidelines are to be debated at a major international HIV conference in Copenhagen, Denmark on March 19-20, 2012.

Related Links:
HIV in Europe
University of Copenhagen



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.